Pancreatic Cancer Breakthrough: Fundraising for Promising New Therapy

A new therapeutic approach is offering hope in the fight against pancreatic cancer, a disease known for its aggressive nature and poor prognosis. Researchers in Spain have developed a triple-drug therapy that has demonstrated the complete elimination of pancreatic tumors in mice, prompting a fundraising campaign to support further research and eventual human clinical trials.

Pancreatic cancer is notoriously difficult to treat. Often diagnosed late – in over 60% of cases, the cancer has already reached Stage 4 – it presents with vague symptoms like back pain, indigestion, nausea, fatigue, and bloating, which are frequently dismissed as other, less serious conditions. The tumor’s biology often leads to resistance to traditional chemotherapy within months of treatment initiation. Currently, most drugs for pancreatic cancer target KRS, a genetic mutation present in approximately 90% of patients, but tumors quickly develop resistance, limiting their effectiveness.

The breakthrough, originating from the National Cancer Research Centre (CNIO) in Spain, centers around a triple therapy designed to overcome this resistance. Published recently in the journal PNAS, the research details how combining an experimental KRAS inhibitor with a protein degrader and a drug commonly used to treat lung cancer effectively targets KRAS at three distinct points. This multi-pronged approach led to the permanent disappearance of pancreatic tumors in the mice studied, with minimal observed side effects.

The CNIO team’s strategy focuses on simultaneously disrupting the KRAS pathway through multiple mechanisms. This differs from existing treatments that target only one aspect of the pathway, allowing the cancer to adapt and become resistant. By hitting KRAS from three angles, the therapy appears to prevent the development of resistance, leading to complete tumor elimination in the animal models.

Dr. Mariano Barbacid, a Spanish oncologist leading the research, is at the center of a fundraising effort launched by Fundación CRIS Contra el Cáncer to accelerate the next phases of development. The funds will be used to conduct advanced preclinical studies, refine drug combinations and dosages, and test the therapy in a wider range of experimental models before seeking approval for clinical trials in humans.

A key component of the research involves innovative approaches, including the use of PROTAC-based compounds. These compounds are designed to selectively degrade cancer-causing proteins within tumor cells. While promising, these therapies require extensive pharmaceutical development to ensure safety, stability, and scalability for human use.

Pancreatic ductal adenocarcinoma remains one of the deadliest cancers, largely due to late diagnosis and limited treatment options. In Spain, thousands of new cases are diagnosed annually, and the five-year survival rate remains below 10%. The fundraising campaign aims to directly support the research, potentially leading to new therapeutic options for patients facing this challenging diagnosis.

The study authors emphasize that translating these promising results from mice to humans will be a complex and lengthy process. Optimizing the triple combination therapy for clinical use will require significant further investigation. However, the initial findings represent a significant step forward in the search for more effective treatments for pancreatic cancer, offering a glimmer of hope for patients and their families.

While the research is still in its early stages, the complete elimination of tumors in mice is a remarkable achievement. The success of this triple therapy highlights the potential of targeting multiple pathways simultaneously to overcome drug resistance and improve treatment outcomes in pancreatic cancer. Further research and clinical trials will be crucial to determine whether these findings can be replicated in humans and ultimately lead to a new era of treatment for this devastating disease.